Key Insights on Gross Profit: Teva Pharmaceutical Industries Limited vs United Therapeutics Corporation

Teva vs. United Therapeutics: A Decade of Gross Profit Trends

__timestampTeva Pharmaceutical Industries LimitedUnited Therapeutics Corporation
Wednesday, January 1, 2014110560000001162636000
Thursday, January 1, 2015113560000001396725000
Friday, January 1, 2016118590000001526100000
Sunday, January 1, 2017108250000001619600000
Monday, January 1, 201882960000001429100000
Tuesday, January 1, 201975360000001331200000
Wednesday, January 1, 202077250000001375200000
Friday, January 1, 202175940000001563000000
Saturday, January 1, 202269730000001789600000
Sunday, January 1, 202376460000002070000000
Monday, January 1, 20248064000000
Loading chart...

Infusing magic into the data realm

A Tale of Two Pharmaceutical Giants: Teva vs. United Therapeutics

In the ever-evolving pharmaceutical industry, understanding financial health is crucial. This analysis compares the gross profit trends of Teva Pharmaceutical Industries Limited and United Therapeutics Corporation from 2014 to 2023.

Teva, a global leader in generic medicines, saw its gross profit peak in 2016, only to decline by approximately 41% by 2022. This decline reflects challenges in the generics market and increased competition. In contrast, United Therapeutics, known for its innovative therapies, experienced a steady rise in gross profit, culminating in a 78% increase over the same period.

By 2023, United Therapeutics' gross profit reached its highest, showcasing its resilience and strategic focus on niche markets. This comparison highlights the contrasting paths of these two companies, offering insights into the broader pharmaceutical landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025